SCHMID, Christoph, Myriam LABOPIN, Arnon NAGLER, Dietger NIEDERWIESER, Luca CASTAGNA, Reza TABRIZI, Michael STADLER, Juergen KUBALL, Jan CORNELISSEN, Jiří VORLÍČEK, Gerard SOCIÉ, Michele FALDA, Lars VINDELOV, Per LJUNGMAN, Graham JACKSON, Nicolaus KROEGER, Andreas RANK, Emmanuelle POLGE, Vanderson ROCHA a Mohamad MOHTY. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood, Washington DC, USA: American Society of Hematology, 2012, roč. 119, č. 6, s. 1599-1606. ISSN 0006-4971. doi:10.1182/blood-2011-08-375840.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Autoři SCHMID, Christoph, Myriam LABOPIN, Arnon NAGLER, Dietger NIEDERWIESER, Luca CASTAGNA, Reza TABRIZI, Michael STADLER, Juergen KUBALL, Jan CORNELISSEN, Jiří VORLÍČEK, Gerard SOCIÉ, Michele FALDA, Lars VINDELOV, Per LJUNGMAN, Graham JACKSON, Nicolaus KROEGER, Andreas RANK, Emmanuelle POLGE, Vanderson ROCHA a Mohamad MOHTY.
Vydání Blood, Washington DC, USA, American Society of Hematology, 2012, 0006-4971.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 9.060
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1182/blood-2011-08-375840
UT WoS 000300420900037
Klíčová slova anglicky ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; 1ST INTERNATIONAL WORKSHOP; GRAFT-VERSUS-LEUKEMIA; LOW-DOSE AZACITIDINE; MYELODYSPLASTIC SYNDROMES; HEMATOLOGIC MALIGNANCIES; MYELOABLATIVE THERAPY; PATIENTS OLDER; WORKING PARTY
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 23. 4. 2014 15:10.
Anotace
Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute Leukemia Working Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% +/- 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT > 5 months (hazard ratio [HR] = 0.50, 95% confidence interval [CI], 0.37-0.67, P < .001), bone marrow blasts less than 27% (HR = 0.53, 95% CI, 0.40-0.72, P < .001), and absence of acute GVHD after HSCT (HR = 0.67, 95% CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32% +/- 7%, 19% +/- 4%, and 4% +/- 2% at 2 years (P < .0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation.
Typ Název Vložil/a Vloženo Práva
Schmid-Treatment_Blood_.pdf   Verze souboru Pospíšilíková, V. 14. 2. 2013

Práva

Právo číst
 
Právo vkládat
 
Právo spravovat
  • osoba Ing. Mgr. Věra Pospíšilíková, učo 9005
Atributy
 
Vytisknout
Požádat autora o autorský výtisk Zobrazeno: 21. 9. 2020 00:12